NINE HEALTH CIC

Company limited by guarantee

Company Registration Number:
07717993 (England and Wales)

Unaudited statutory accounts for the year ended 28 September 2024

Period of accounts

Start date: 29 September 2023

End date: 28 September 2024

NINE HEALTH CIC

Contents of the Financial Statements

for the Period Ended 28 September 2024

Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

NINE HEALTH CIC

Profit And Loss Account

for the Period Ended 28 September 2024

2024 2023


£

£
Turnover: 0 8,350
Cost of sales: 0 0
Gross profit(or loss): 0 8,350
Administrative expenses: ( 2,362 ) ( 2,716 )
Operating profit(or loss): (2,362) 5,634
Interest payable and similar charges: ( 1,838 ) ( 1,740 )
Profit(or loss) before tax: (4,200) 3,894
Profit(or loss) for the financial year: (4,200) 3,894

NINE HEALTH CIC

Balance sheet

As at 28 September 2024

Notes 2024 2023


£

£
Fixed assets
Intangible assets:   0 0
Tangible assets: 3 1 1
Investments: 4 8 8
Total fixed assets: 9 9
Current assets
Debtors: 5 6,478 7,628
Cash at bank and in hand: 4 4
Total current assets: 6,482 7,632
Creditors: amounts falling due within one year: 6 ( 33,254 ) ( 33,562 )
Net current assets (liabilities): (26,772) (25,930)
Total assets less current liabilities: (26,763) ( 25,921)
Creditors: amounts falling due after more than one year: 7 ( 119,982 ) ( 116,624 )
Total net assets (liabilities): (146,745) (142,545)
Members' funds
Profit and loss account: (146,745) ( 142,545)
Total members' funds: ( 146,745) (142,545)

The notes form part of these financial statements

NINE HEALTH CIC

Balance sheet statements

For the year ending 28 September 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 26 June 2025
and signed on behalf of the board by:

Name: Philip Howard Davies
Status: Director

The notes form part of these financial statements

NINE HEALTH CIC

Notes to the Financial Statements

for the Period Ended 28 September 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

NINE HEALTH CIC

Notes to the Financial Statements

for the Period Ended 28 September 2024

  • 2. Employees

    2024 2023
    Average number of employees during the period 2 2

NINE HEALTH CIC

Notes to the Financial Statements

for the Period Ended 28 September 2024

3. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 29 September 2023 1 1
Additions
Disposals
Revaluations
Transfers
At 28 September 2024 1 1
Depreciation
At 29 September 2023 0 0
Charge for year 0 0
On disposals
Other adjustments
At 28 September 2024 0 0
Net book value
At 28 September 2024 1 1
At 28 September 2023 1 1

NINE HEALTH CIC

Notes to the Financial Statements

for the Period Ended 28 September 2024

4. Fixed assets investments note

Investment in subsidiary

NINE HEALTH CIC

Notes to the Financial Statements

for the Period Ended 28 September 2024

5. Debtors

2024 2023
£ £
Trade debtors 6,478 7,628
Total 6,478 7,628

NINE HEALTH CIC

Notes to the Financial Statements

for the Period Ended 28 September 2024

6. Creditors: amounts falling due within one year note

2024 2023
£ £
Bank loans and overdrafts 15,872 16,119
Trade creditors 490 490
Taxation and social security 7,722 7,722
Accruals and deferred income 6,788 6,249
Other creditors 2,382 2,982
Total 33,254 33,562

NINE HEALTH CIC

Notes to the Financial Statements

for the Period Ended 28 September 2024

7. Creditors: amounts falling due after more than one year note

2024 2023
£ £
Bank loans and overdrafts 13,337 12,879
Other creditors 106,645 103,745
Total 119,982 116,624

COMMUNITY INTEREST ANNUAL REPORT

NINE HEALTH CIC

Company Number: 07717993 (England and Wales)

Year Ending: 28 September 2024

Company activities and impact

Nine Health CIC was part of a consortium that won an award from the National Institute of Healthcare Research for a feasibility study to pioneer the use of Artificial Intelligence in healthcare. The study focussed on hard-to heal wounds for the lower limb, (Venous leg ulcers and diabetic foot ulcers). This is an enormous problem for the NHS which in 2017 spent 5 billion on VLUs and DFUs, in 2020 this had risen to 8 billion now it is more than 8.5 billion. People with these wounds suffer pain, amputations, and death. Many of the causal factors are modifiable e.g., lifestyle factors, however, there is great inconsistency in treatment and a shortage of tissue viability nurses. Nine Health was able to offer data analysis using innovative methods to produce predictive results such as those most likely to develop a hard-to-heal wound enabling staff to prevent the wound in the first place. Other important factors were the role of vitamin B12 and HBAIc. Currently, blood tests are not always routinely done in these patients so now these factors cannot be detected. The introduction of a routine blood test would enable this to happen preventing or speeding up the wound healing. As we were not successful in our resubmission in 2024, we are trying again in 2025 and in negotiation to attract overseas funding (Hong Kong) to complete the work. We have published a synopsis of this work in the British Medical Journal and spoken at several events online and at local Universities. We completed work on the CORA (COVID remote assistant) prototype chatbot which finds and provides support to people with problems such as mental health, financial; problems, support for cancer patients and have started exploring what other areas in the NHS we can apply the technology to. We have now completed a prototype waiting list management tool and are seeking NHS partners to take this forward. This will help shorten waits and ensure that patients do not worsen whilst waiting. We have continued working with a consortium of architects, NHS providers and leading experts in Dementia to develop a high-tech evidence-based service for people and their families with early onset dementia which would provide the following services: tech activity centre will offer: Wellness screening (whole families) offered by Health care Professionals (HCP) using Nine Health Global's (NHG) and other's A.I. tools Physical fitness, cognitive stimulation and social activities including a tea and coffee shop (open to the public) will be offered onsite. Supported by physical fitness/cognitive activities being offered remotely for those attending the centres or remote users. Physical fitness activities will be linked up to London Sport and local services Nutritional advice, lifestyle planning, referral, and appropriate therapeutic interventions e.g., a full range of psychological services for every member Wellbeing services for families and caregivers including 1:1 counselling, group counselling and couples or marriage support Education and Health promotion and training for clients, families, HCPs and other health and care staff. Training will be accredited with Continuing Professional Development (CPD) and will be delivered using a hybrid model of face-to-face and remote means; allowing for the training to be available and sold in the U.K. and Internationally. An online shop selling high-tech equipment e.g., apps/games/sleep hub A repository for data for research services, subject to sharing agreements following Health Research Authority and ethical approvals Ongoing research will be at the heart of every centre. Building on research already carried out and published by the people involved in the project design and development; ensuring that the centres continue to evolve innovatively Dementia is a huge global challenge affecting over 55 million people with 10 million new cases diagnosed each year. In the U.K. 850,000 people are living with dementia. Whilst it primarily affects people over the age of 65years we know that: Mental quickness reduces from age 25yrs (Harvard Health Publishing, 2017) Cognitive decline begins from age 45yrs (BMJ, 2012) Cognitive decline speeds up at retirement (Celidoni, Dal Bianco and Weber, 2017) Our proposal is to develop state-of-the-art wellness activity centres. Research shows that the progression of dementia can be slowed down and the risk of developing dementia decreased if therapeutic interventions are started early enough, enabling people to age better cognitively and physically. With the knowledge that the cost of dementia care in the UK is currently £26 billion (Lewis et al., 2015), Alzheimer's Research UK commissioned the Office of Health Economics Consulting (OHE), to model the grow- ing prevalence and costs of dementia in the UK and estimate the impact new treatments could have if they were introduced at the beginning of 2020. The OHE's model shows that new interventions to prevent and treat dementia could change the longer-term picture dramatically. Delaying the onset of dementia by five years in the UK from 2020 could reduce the projected number of people with dementia in 2050 by one-third (666,000); reducing the need for informal care by 566,000. In addition, the costs of care would be reduced from £59 billion to £ 38 billion in 2050; a saving of £21 billion (OHE, 2020). We have partnered with Your Health Care another large London based Community interest Company and have applied to UKRI and the Alzheimer's Society Longitudinal Prize fund for research funding to set up one centre managed by Your Healthcare. We are waiting to hear whether these have been successful. We have submitted an EU Horizon research bid with The College of Surgeons in Ireland to develop Trustworthy Artifical Intelligence tools in the cardiovascular and brain health areas we are waiting to hear the outcome.

Consultation with stakeholders

No consultation with stakeholders

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
17 June 2025

And signed on behalf of the board by:
Name: Philip Howard Davies
Status: Director